ARGX Stock Analysis: Buy, Sell, or Hold?
ARGX - argenx SE American Depositary Shares
$834.06
-19.76 (-2.31%)
▼
5d:
-6.16%
30d:
-11.24%
90d:
+6.45%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Oct 22, 2026
Get Alerted When ARGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ARGX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ARGX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$1904.58
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$1182.59
29.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ARGX is currently trading at $834.06, which is considered oversold relative to its 30-day fair value range of $858.32 to $915.09. From a valuation perspective, the stock is trading at a discount (Forward PE: 21.8) compared to its historical average (27.7). Remarkably, the market is currently pricing in an annual earnings decline of 7.7% over the next few years. This pessimistic expectation contrasts with the company's recent 95.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ARGX is showing support break momentum. The price is currently testing key support at $826.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $1079.55 (+26.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ARGX is showing support break momentum. The price is currently testing key support at $826.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $1079.55 (+26.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$858.32 -
$915.09
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 26.4% below Wall St target ($1079.55)
- CAUTION: Recommendation downgraded due to -6.2% 5-day decline
Trading Range Analysis
30-Day Trading Range
$858.32 -
$915.09
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$826.45
Resistance Level
$935.88
Current Trend
Support Break
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.82
Wall Street Target
$1079.55
(+26.4%)
Revenue Growth (YoY)
59.3%
Earnings Growth (YoY)
95.2%
Profit Margin
32.3%
Valuation Discount vs History
-7.7% cheaper
PE vs Historical
21.8 vs 27.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.7%
(market-implied from PE analysis)
1-Year Target
$788.08
(-8%)
2-Year Target
$727.39
(-15%)
3-Year Target
$671.38
(-21%)
3-Yr Target (if PE normalizes)
(PE: 22→28)
$852.11
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 36.8%)
$2187.53
(+156%)
Base:
(SPY PE: 20.7, Growth: 36.8%)
$2077.79
(+143%)
Bear:
(PE: 17.6, Growth: 36.8%)
$1766.12
(+107%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (34x PE), but valuation improves significantly next year (22x PE) as earnings recover.
Trailing PE: 33.65 | Current EPS (TTM): $25.93
Bull Case
$1448.14
(+70%)
Analyst growth 50.9%, PE expands to 37.0
Base Case
$1316.49
(+54%)
Market implied 50.9%, PE stable at 33.7
Bear Case
$593.35
(-31%)
Severe decline -20.0%, PE contracts to 28.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 21.8 to 27.7
Stabilization Target:
$1083.66
(+26.9%)
PE Expansion Potential:
+26.9%
Share & Embed Analysis
Last updated: August 03, 2026 2:01 PM ET
Data refreshes hourly during market hours. Next update: 3:01 PM
Data refreshes hourly during market hours. Next update: 3:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$267 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 56 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$33 | 58 HOLD |
